Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by AstraZeneca, we had the pleasure of speaking with Charu Aggarwal, MD, MPH, a medical oncologist at Abramson Cancer Center of Penn Medicine and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine, to discuss the 5-year survival data from the phase 3 PACIFIC trial (NCT02125461) that were presented at the 2021 ASCO Annual Meeting.

Updated results from the trial showed that durvalumab (Imfinzi) following chemoradiotherapy was associated with robust and sustained overall survival (OS) and progression-free survival (PFS) benefits in patients with unresectable stage III non–small cell lung cancer (NSCLC) whose disease had not progressed after concurrent chemoradiotherapy.

Specifically, at a median follow-up of 34.2 months, the median OS was 47.5 months with durvalumab vs 29.1 months with placebo (HR, 0.72; 95% CI, 0.59-0.89). Moreover, the median PFS was 16.9 months vs 5.6 months, respectively (HR, 0.55; 95% CI, 0.45-0.68).

Of note, an estimated 42.9% of patients randomized to durvalumab remained alive at 5 years vs 33.4% of patients randomized to placebo. Additionally, an estimated 33.1% of durvalumab-treated patients remained alive without disease progression vs 19% of placebo-treated patients.

We also sat down with Nicolas Girard, MD, PhD, a professor of respiratory medicine at Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute, in Paris, France, to discuss the results of the PACIFIC-R trial (NCT03798535) that were presented during the 2021 ESMO Congress.

Results from PACIFIC-R recapitulated the benefit that has been reported with durvalumab following concurrent chemoradiotherapy in patients with unresectable stage III NSCLC in a real-world setting.

In our exclusive interview, Aggarwal and Girard discussed the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III NSCLC.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.